Pan Zheng - Academia.edu (original) (raw)

Papers by Pan Zheng

Research paper thumbnail of Signalling through FOXP3 as an X-linked tumor suppressor

The international journal of biochemistry & cell biology, 2010

The FOXP3 (forkhead box P3) gene is a member of forkhead winged helix family transcription factor... more The FOXP3 (forkhead box P3) gene is a member of forkhead winged helix family transcription factors and functions as both a transcriptional activator and a repressor. FOXP3 dysfunction is responsible for an X-linked autoimmune syndrome: immune dysregulation, polyendopathy, enterophathy, X-linked syndrome. In addition to its role as an essential transcription factor in regulatory T cells, the FOXP3 gene is an epithelial cell-intrinsic tumor suppressor for breast and prostate cancers. We will focus on the FOXP3 signalling pathway in epithelial cells and discuss how genetic and/or epigenetic inactivation of the FOXP3 contributes to the malignant transformation of cells.

Research paper thumbnail of On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen

Cancer research, Jan 15, 2001

Because of the low frequency of antigen-specific T cells, early events in the activation of tumor... more Because of the low frequency of antigen-specific T cells, early events in the activation of tumor-specific T cells in vivo have not been well characterized. There is still no direct documentation on where the clonal expansion begins and how tumor antigens are presented to the host CD8 T cells to initiate it. Here we used transgenic T cells specific for a natural tumor antigen P1A to evaluate the kinetics, location, and modes of antigen presentation for initiating CTL response in vivo. Our results demonstrate that the initial activation of P1A-specific T cells takes place in the lymphoid organs. The activated T cells then migrate into tumors, where they undergo accelerated division and acquire distinct activation markers. The site of initiation cannot be altered by either local expression of costimulatory molecules or by intratumor injection of naïve T cells. Moreover, using genetic models that allow only one mode of antigen presentation, we show here that both cross-presentation of ...

Research paper thumbnail of Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells

Cancer research, 2001

MHC class I-restricted tumor antigen can be presented to CD8+ T cells by two distinct mechanisms.... more MHC class I-restricted tumor antigen can be presented to CD8+ T cells by two distinct mechanisms. Direct presentation involves degradation of cytosolic proteins by the proteosome into peptides, transport of the peptides across the endoplasmic reticulum membrane, and expression of the MHC-peptide complex on the tumor cell surface. Cross-presentation, on the other hand, involves uptake and intracellular processing of the tumor antigen by host antigen-presenting cells. Whereas it is clear that cross-presentation is necessary and sufficient for the induction of memory CTLs, it has not been tested whether such presentation is sufficient to induce effector CTLs. Here we analyzed the requirements of direct antigen presentation for the induction of effector and memory antitumor CTLs using a MHC class I- mutant incapable of direct antigen presentation and its parent, the MHC class I+ J558 cell line. We report that in comparison with the MHC class I+ tumor cell, the MHC class I- mutant induce...

Research paper thumbnail of B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8 � T Lymphocytes In Vivo

B7H/B7RP (hereby called B7H) is a new member of the B7 family of costimulatory molecules and inte... more B7H/B7RP (hereby called B7H) is a new member of the B7 family of costimulatory molecules and interacts with inducible costimulatory molecule (ICOS). Its function for CD8 T cells has not been reported. We report here that expression of B7H on the tumor cells reduced tumori- genicity and induced immunity to subsequent challenge with parental tumor cells. The im- mune protection

Research paper thumbnail of FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene

Research paper thumbnail of Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity

Glycobiology, 2014

Siglec-G/10 is broadly expressed on B cells, dendritic cells and macrophage subsets. It binds str... more Siglec-G/10 is broadly expressed on B cells, dendritic cells and macrophage subsets. It binds strongly to CD24, a small glycosyl-phosphatidylinositol-anchored sialoprotein, in a sialylation-dependent manner. Targeted mutation of Siglecg dramatically elevates the level of natural IgM antibodies and its producer, B1 B cells. Incorporation of Siglec-G ligands to both T-dependent and T-independent immunogens reduces antibody production and induces B-cell tolerance to subsequent antigen challenges. By interacting with CD24, Siglec-G suppresses inflammatory responses to danger (damage)-associated molecular patterns, such as heat-shock proteins and high mobility group protein 1, but not to Toll-like receptor ligands. By a CD24-independent mechanism, Siglec-G has been shown to associate with Cbl to cause degradation of retinoic acid-inducible gene 1 and reduce production of type I interferon in response to RNA virus infection. The negative regulation by Siglec-G/10 may provide a mechanism f...

Research paper thumbnail of Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1

eLife, 2014

Both pathogen- and tissue damage-associated molecular patterns induce inflammation through toll-l... more Both pathogen- and tissue damage-associated molecular patterns induce inflammation through toll-like receptors (TLRs), while sialic acid-binding immunoglobulin superfamily lectin receptors (Siglecs) provide negative regulation. Here we report extensive and direct interactions between these pattern recognition receptors. The promiscuous TLR binders were human SIGLEC-5/9 and mouse Siglec-3/E/F. Mouse Siglec-G did not show appreciable binding to any TLRs tested. Correspondingly, Siglece deletion enhanced dendritic cell responses to all microbial TLR ligands tested, while Siglecg deletion did not affect the responses to these ligands. TLR4 activation triggers Neu1 translocation to cell surface to disrupt TLR4:Siglec-E interaction. Conversely, sialidase inhibitor Neu5Gc2en prevented TLR4 ligand-induced disruption of TLR4:Siglec E/F interactions. Absence of Neu1 in hematopoietic cells or systematic treatment with sialidase inhibitor Neu5Gc2en protected mice against endotoxemia. Our data r...

Research paper thumbnail of Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

Blood, Jan 14, 2014

Acute myeloid leukemia (AML) often relapses following chemotherapy-induced remission and is gener... more Acute myeloid leukemia (AML) often relapses following chemotherapy-induced remission and is generally chemo-resistant. Given the potential role for cancer stem cells in relapse, targeting of the leukemia-initiating cell (LIC) in AML may provide improved outcome following remission induction. However, due to overlap in their self-renewal program with normal hematopoietic stem cells (HSCs), therapeutic targeting of the LIC may have an adverse effect on long-term hematopoietic recovery. Here we used a mouse model of relapsed AML to explore whether the hypoxia-inducible factor (HIF)1α inhibitor echinomycin can be used to treat relapsed AML without affecting host HSCs. We show that echinomycin cured 40% to 60% of mice transplanted with relapsed AML. Bone marrow cells from the cured mice displayed normal composition of HSCs and their progenitors and were as competent as those isolated from nonleukemic mice in competitive repopulation assays. Importantly, in mice with complete remission, e...

Research paper thumbnail of Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis

eLife, 2014

Cell-based studies showed that several Mdm2-binding ribosomal proteins, upon overexpression, stab... more Cell-based studies showed that several Mdm2-binding ribosomal proteins, upon overexpression, stabilize and activate p53. In contrast, here we show in a mouse knockout study that Mdm2-binding ribosomal protein S27-like (Rps27l), upon disruption, activates p53. Germline inactivation of Rps27l triggers ribosomal stress to stabilize Mdm2, which degrades Mdm4 to reduce Mdm2-Mdm4 E3 ligase towards p53, leading to p53-dependent apoptotic depletion of hematopoietic stem cells and postnatal death, which is rescued by Trp53 deletion. Paradoxically, while increased p53 is expected to inhibit tumorigenesis, Rps27l⁻/⁻;Trp53⁺/⁻ mice develop lymphomas at higher incidence with p53 loss-of-heterozygosity and severe genome aneuploidy, suggesting that Rps27l disruption impose a selection pressure against p53. Thus, Rps27l has dual functions in p53 regulation: under Trp53⁺/⁺ background, Rps27l disruption triggers ribosomal stress to induce p53 and apoptosis, whereas under Trp53⁺/⁻ background, Rps27l di...

Research paper thumbnail of Anti4-1BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival but not Clonal Expansion of Tumor-specific CD8 T Cells1

Anti-4-1BB monoclonal antibody (mAb) has been shown to induce antitumor immunity by a CD4/CD8-dep... more Anti-4-1BB monoclonal antibody (mAb) has been shown to induce antitumor immunity by a CD4/CD8-dependent mechanism, but its direct effect on tumor-specific CD8 T cells in tumor rejection is unclear. Here we used transgenic CD8 T cells against the unmutated tumor rejection antigen P1A to analyze whether this mAb can promote CD8 T-cell function against large tumors in the absence of

Research paper thumbnail of FOXP3 controls an miR-146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells

Cancer research, Jan 23, 2015

FOXP3 functions not only as the master regulator in regulatory T cells but also as an X-linked tu... more FOXP3 functions not only as the master regulator in regulatory T cells but also as an X-linked tumor suppressor. The tumor suppressive activity of FOXP3 has been observed in tumor initiation, but its role during tumor progression remains controversial. Moreover, the mechanism of FOXP3-mediated tumor suppressive activity remains largely unknown. Using chromatin immunoprecipitation sequencing, we identified a series of potential FOXP3-targeted microRNAs (miRs) in MCF7 cells. Notably, FOXP3 significantly induced the expression of miR-146a/b. In vitro, FOXP3-induced miR-146a/b prevented tumor cell proliferation and enhanced apoptosis. Functional analyses in vitro and in vivo revealed that FOXP3-induced miR-146a/b negatively regulate NF-κB activation by inhibiting the expression of IRAK1 and TRAF6. In chromatin immunoprecipitation assays, FOXP3 directly bound the promoter region of miR-146a but not of miR-146b, and FOXP3 interacted directly with NF-κB p65 to regulate an miR-146-NF-κB neg...

Research paper thumbnail of On the Role of Unmutated Antigens in Tumor Rejection in Mice with Unperturbed T-cell Repertoires1

We investigate here whether P1A, which was the first CTL-recognized and unmutated tumor antigen t... more We investigate here whether P1A, which was the first CTL-recognized and unmutated tumor antigen to be identified, is a tumor rejection antigen for J558 plasmacytoma in mice with an unperturbed T-cell repertoire. We show that although transgenic mice expressing P1A in the thymus have almost complete deletion of P1A-reactive T cells, they reject the B7-1- transfected J558 at a rate

Research paper thumbnail of Burdens Therapy in Mice with Large Tumor Lymphocytes for Experimental Tumor-Specific Cytolytic T Local Costimulation Reinvigorates

Research paper thumbnail of adult tumor-bearing mice Immune competence of cancer-reactive T cells generated de novo in

Research paper thumbnail of novo in adult tumor-bearing mice

Research paper thumbnail of Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice

The impact of timing of antigen introduc- tion into fetus and neonates leads to the suggestion th... more The impact of timing of antigen introduc- tion into fetus and neonates leads to the suggestion that pre-existing antigens are tolerogenic to immunocompetent cells generated thereafter. This hypothesis pre- dicts that in patients with cancer who are undergoing bone marrow transplanta- tion, newly produced T cells with specific- ity for pre-existing tumor cells will be inactivated by the tumor antigens

Research paper thumbnail of Protooncogene PML controls genes devoted to MHC class I antigen presentation

Nature, 1998

Fragments of foreign antigens associated with class I molecules of the major histocompatibility c... more Fragments of foreign antigens associated with class I molecules of the major histocompatibility complex (MHC) are presented at the cell surface to elicit an immune response. This presentation requires the coordinated expression of several genes contained in the MHC, including those encoding the MHC class I heavy chain, the proteins LMP-2 and LMP-7, which are involved in the proteasomal degradation

Research paper thumbnail of Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation

Nature communications, 2015

CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tu... more CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tumour-suppressor gene that functions in a context-dependent manner. Here we show that both targeted mutation and short hairpin RNA (shRNA) silencing of CD24 retard the growth, progression and metastasis of prostate cancer. CD24 competitively inhibits ARF binding to NPM, resulting in decreased ARF, increase MDM2 and decrease levels of p53 and the p53 target p21/CDKN1A. CD24 silencing prevents functional inactivation of p53 by both somatic mutation and viral oncogenes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen. In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels. These data provide a general mechanism for functional inactivation of ARF and reveal an important cellular context for genetic and viral inactivation of TP53.

Research paper thumbnail of Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells

Journal of immunology (Baltimore, Md. : 1950), Jan 15, 2014

CD24 binds to and suppresses inflammation triggered by danger-associated molecular patterns such ... more CD24 binds to and suppresses inflammation triggered by danger-associated molecular patterns such as heat shock proteins (HSPs) and high-mobility group box 1. Paradoxically, CD24 has been shown to enhance autoimmune disease. In this study, we attempt to reconcile this paradox by deletion of CD24 (24KO) in a lupus-like disease model driven by forced expression of HSP gp96 at the cell surface (transgenic mice [tm]). As expected, tm24KO mice showed increased CD11c(+) dendritic cell activation coupled to a significant increase in dendritic cell-specific IL-12 production compared with tm mice. However, tm24KO mice showed less CD4 T cell activation and peripheral inflammatory cytokine production in comparison with tm mice. We characterized an enhanced immune suppressive milieu in tm24KO mice distinguished by increased TGF-β and greater regulatory T cell-suppressive capacity. We found greater absolute numbers of myeloid-derived suppressor cells (MDSCs) in tm24KO mice and showed that the Ly6...

Research paper thumbnail of Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies

Although results from preclinical studies in animal models have proven the con- cept for use of a... more Although results from preclinical studies in animal models have proven the con- cept for use of anti-cytotoxic T-lympho- cyte antigen 4 (CTLA-4) antibodies in cancer immunotherapy, 2 major obstacles have hindered their successful applica- tion for human cancer therapy. First, the lack of in vitro correlates of the antitumor effect of the antibodies makes it difficult to screen for the

Research paper thumbnail of Signalling through FOXP3 as an X-linked tumor suppressor

The international journal of biochemistry & cell biology, 2010

The FOXP3 (forkhead box P3) gene is a member of forkhead winged helix family transcription factor... more The FOXP3 (forkhead box P3) gene is a member of forkhead winged helix family transcription factors and functions as both a transcriptional activator and a repressor. FOXP3 dysfunction is responsible for an X-linked autoimmune syndrome: immune dysregulation, polyendopathy, enterophathy, X-linked syndrome. In addition to its role as an essential transcription factor in regulatory T cells, the FOXP3 gene is an epithelial cell-intrinsic tumor suppressor for breast and prostate cancers. We will focus on the FOXP3 signalling pathway in epithelial cells and discuss how genetic and/or epigenetic inactivation of the FOXP3 contributes to the malignant transformation of cells.

Research paper thumbnail of On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen

Cancer research, Jan 15, 2001

Because of the low frequency of antigen-specific T cells, early events in the activation of tumor... more Because of the low frequency of antigen-specific T cells, early events in the activation of tumor-specific T cells in vivo have not been well characterized. There is still no direct documentation on where the clonal expansion begins and how tumor antigens are presented to the host CD8 T cells to initiate it. Here we used transgenic T cells specific for a natural tumor antigen P1A to evaluate the kinetics, location, and modes of antigen presentation for initiating CTL response in vivo. Our results demonstrate that the initial activation of P1A-specific T cells takes place in the lymphoid organs. The activated T cells then migrate into tumors, where they undergo accelerated division and acquire distinct activation markers. The site of initiation cannot be altered by either local expression of costimulatory molecules or by intratumor injection of naïve T cells. Moreover, using genetic models that allow only one mode of antigen presentation, we show here that both cross-presentation of ...

Research paper thumbnail of Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells

Cancer research, 2001

MHC class I-restricted tumor antigen can be presented to CD8+ T cells by two distinct mechanisms.... more MHC class I-restricted tumor antigen can be presented to CD8+ T cells by two distinct mechanisms. Direct presentation involves degradation of cytosolic proteins by the proteosome into peptides, transport of the peptides across the endoplasmic reticulum membrane, and expression of the MHC-peptide complex on the tumor cell surface. Cross-presentation, on the other hand, involves uptake and intracellular processing of the tumor antigen by host antigen-presenting cells. Whereas it is clear that cross-presentation is necessary and sufficient for the induction of memory CTLs, it has not been tested whether such presentation is sufficient to induce effector CTLs. Here we analyzed the requirements of direct antigen presentation for the induction of effector and memory antitumor CTLs using a MHC class I- mutant incapable of direct antigen presentation and its parent, the MHC class I+ J558 cell line. We report that in comparison with the MHC class I+ tumor cell, the MHC class I- mutant induce...

Research paper thumbnail of B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8 � T Lymphocytes In Vivo

B7H/B7RP (hereby called B7H) is a new member of the B7 family of costimulatory molecules and inte... more B7H/B7RP (hereby called B7H) is a new member of the B7 family of costimulatory molecules and interacts with inducible costimulatory molecule (ICOS). Its function for CD8 T cells has not been reported. We report here that expression of B7H on the tumor cells reduced tumori- genicity and induced immunity to subsequent challenge with parental tumor cells. The im- mune protection

Research paper thumbnail of FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene

Research paper thumbnail of Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity

Glycobiology, 2014

Siglec-G/10 is broadly expressed on B cells, dendritic cells and macrophage subsets. It binds str... more Siglec-G/10 is broadly expressed on B cells, dendritic cells and macrophage subsets. It binds strongly to CD24, a small glycosyl-phosphatidylinositol-anchored sialoprotein, in a sialylation-dependent manner. Targeted mutation of Siglecg dramatically elevates the level of natural IgM antibodies and its producer, B1 B cells. Incorporation of Siglec-G ligands to both T-dependent and T-independent immunogens reduces antibody production and induces B-cell tolerance to subsequent antigen challenges. By interacting with CD24, Siglec-G suppresses inflammatory responses to danger (damage)-associated molecular patterns, such as heat-shock proteins and high mobility group protein 1, but not to Toll-like receptor ligands. By a CD24-independent mechanism, Siglec-G has been shown to associate with Cbl to cause degradation of retinoic acid-inducible gene 1 and reduce production of type I interferon in response to RNA virus infection. The negative regulation by Siglec-G/10 may provide a mechanism f...

Research paper thumbnail of Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1

eLife, 2014

Both pathogen- and tissue damage-associated molecular patterns induce inflammation through toll-l... more Both pathogen- and tissue damage-associated molecular patterns induce inflammation through toll-like receptors (TLRs), while sialic acid-binding immunoglobulin superfamily lectin receptors (Siglecs) provide negative regulation. Here we report extensive and direct interactions between these pattern recognition receptors. The promiscuous TLR binders were human SIGLEC-5/9 and mouse Siglec-3/E/F. Mouse Siglec-G did not show appreciable binding to any TLRs tested. Correspondingly, Siglece deletion enhanced dendritic cell responses to all microbial TLR ligands tested, while Siglecg deletion did not affect the responses to these ligands. TLR4 activation triggers Neu1 translocation to cell surface to disrupt TLR4:Siglec-E interaction. Conversely, sialidase inhibitor Neu5Gc2en prevented TLR4 ligand-induced disruption of TLR4:Siglec E/F interactions. Absence of Neu1 in hematopoietic cells or systematic treatment with sialidase inhibitor Neu5Gc2en protected mice against endotoxemia. Our data r...

Research paper thumbnail of Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

Blood, Jan 14, 2014

Acute myeloid leukemia (AML) often relapses following chemotherapy-induced remission and is gener... more Acute myeloid leukemia (AML) often relapses following chemotherapy-induced remission and is generally chemo-resistant. Given the potential role for cancer stem cells in relapse, targeting of the leukemia-initiating cell (LIC) in AML may provide improved outcome following remission induction. However, due to overlap in their self-renewal program with normal hematopoietic stem cells (HSCs), therapeutic targeting of the LIC may have an adverse effect on long-term hematopoietic recovery. Here we used a mouse model of relapsed AML to explore whether the hypoxia-inducible factor (HIF)1α inhibitor echinomycin can be used to treat relapsed AML without affecting host HSCs. We show that echinomycin cured 40% to 60% of mice transplanted with relapsed AML. Bone marrow cells from the cured mice displayed normal composition of HSCs and their progenitors and were as competent as those isolated from nonleukemic mice in competitive repopulation assays. Importantly, in mice with complete remission, e...

Research paper thumbnail of Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis

eLife, 2014

Cell-based studies showed that several Mdm2-binding ribosomal proteins, upon overexpression, stab... more Cell-based studies showed that several Mdm2-binding ribosomal proteins, upon overexpression, stabilize and activate p53. In contrast, here we show in a mouse knockout study that Mdm2-binding ribosomal protein S27-like (Rps27l), upon disruption, activates p53. Germline inactivation of Rps27l triggers ribosomal stress to stabilize Mdm2, which degrades Mdm4 to reduce Mdm2-Mdm4 E3 ligase towards p53, leading to p53-dependent apoptotic depletion of hematopoietic stem cells and postnatal death, which is rescued by Trp53 deletion. Paradoxically, while increased p53 is expected to inhibit tumorigenesis, Rps27l⁻/⁻;Trp53⁺/⁻ mice develop lymphomas at higher incidence with p53 loss-of-heterozygosity and severe genome aneuploidy, suggesting that Rps27l disruption impose a selection pressure against p53. Thus, Rps27l has dual functions in p53 regulation: under Trp53⁺/⁺ background, Rps27l disruption triggers ribosomal stress to induce p53 and apoptosis, whereas under Trp53⁺/⁻ background, Rps27l di...

Research paper thumbnail of Anti4-1BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival but not Clonal Expansion of Tumor-specific CD8 T Cells1

Anti-4-1BB monoclonal antibody (mAb) has been shown to induce antitumor immunity by a CD4/CD8-dep... more Anti-4-1BB monoclonal antibody (mAb) has been shown to induce antitumor immunity by a CD4/CD8-dependent mechanism, but its direct effect on tumor-specific CD8 T cells in tumor rejection is unclear. Here we used transgenic CD8 T cells against the unmutated tumor rejection antigen P1A to analyze whether this mAb can promote CD8 T-cell function against large tumors in the absence of

Research paper thumbnail of FOXP3 controls an miR-146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells

Cancer research, Jan 23, 2015

FOXP3 functions not only as the master regulator in regulatory T cells but also as an X-linked tu... more FOXP3 functions not only as the master regulator in regulatory T cells but also as an X-linked tumor suppressor. The tumor suppressive activity of FOXP3 has been observed in tumor initiation, but its role during tumor progression remains controversial. Moreover, the mechanism of FOXP3-mediated tumor suppressive activity remains largely unknown. Using chromatin immunoprecipitation sequencing, we identified a series of potential FOXP3-targeted microRNAs (miRs) in MCF7 cells. Notably, FOXP3 significantly induced the expression of miR-146a/b. In vitro, FOXP3-induced miR-146a/b prevented tumor cell proliferation and enhanced apoptosis. Functional analyses in vitro and in vivo revealed that FOXP3-induced miR-146a/b negatively regulate NF-κB activation by inhibiting the expression of IRAK1 and TRAF6. In chromatin immunoprecipitation assays, FOXP3 directly bound the promoter region of miR-146a but not of miR-146b, and FOXP3 interacted directly with NF-κB p65 to regulate an miR-146-NF-κB neg...

Research paper thumbnail of On the Role of Unmutated Antigens in Tumor Rejection in Mice with Unperturbed T-cell Repertoires1

We investigate here whether P1A, which was the first CTL-recognized and unmutated tumor antigen t... more We investigate here whether P1A, which was the first CTL-recognized and unmutated tumor antigen to be identified, is a tumor rejection antigen for J558 plasmacytoma in mice with an unperturbed T-cell repertoire. We show that although transgenic mice expressing P1A in the thymus have almost complete deletion of P1A-reactive T cells, they reject the B7-1- transfected J558 at a rate

Research paper thumbnail of Burdens Therapy in Mice with Large Tumor Lymphocytes for Experimental Tumor-Specific Cytolytic T Local Costimulation Reinvigorates

Research paper thumbnail of adult tumor-bearing mice Immune competence of cancer-reactive T cells generated de novo in

Research paper thumbnail of novo in adult tumor-bearing mice

Research paper thumbnail of Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice

The impact of timing of antigen introduc- tion into fetus and neonates leads to the suggestion th... more The impact of timing of antigen introduc- tion into fetus and neonates leads to the suggestion that pre-existing antigens are tolerogenic to immunocompetent cells generated thereafter. This hypothesis pre- dicts that in patients with cancer who are undergoing bone marrow transplanta- tion, newly produced T cells with specific- ity for pre-existing tumor cells will be inactivated by the tumor antigens

Research paper thumbnail of Protooncogene PML controls genes devoted to MHC class I antigen presentation

Nature, 1998

Fragments of foreign antigens associated with class I molecules of the major histocompatibility c... more Fragments of foreign antigens associated with class I molecules of the major histocompatibility complex (MHC) are presented at the cell surface to elicit an immune response. This presentation requires the coordinated expression of several genes contained in the MHC, including those encoding the MHC class I heavy chain, the proteins LMP-2 and LMP-7, which are involved in the proteasomal degradation

Research paper thumbnail of Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation

Nature communications, 2015

CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tu... more CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tumour-suppressor gene that functions in a context-dependent manner. Here we show that both targeted mutation and short hairpin RNA (shRNA) silencing of CD24 retard the growth, progression and metastasis of prostate cancer. CD24 competitively inhibits ARF binding to NPM, resulting in decreased ARF, increase MDM2 and decrease levels of p53 and the p53 target p21/CDKN1A. CD24 silencing prevents functional inactivation of p53 by both somatic mutation and viral oncogenes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen. In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels. These data provide a general mechanism for functional inactivation of ARF and reveal an important cellular context for genetic and viral inactivation of TP53.

Research paper thumbnail of Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells

Journal of immunology (Baltimore, Md. : 1950), Jan 15, 2014

CD24 binds to and suppresses inflammation triggered by danger-associated molecular patterns such ... more CD24 binds to and suppresses inflammation triggered by danger-associated molecular patterns such as heat shock proteins (HSPs) and high-mobility group box 1. Paradoxically, CD24 has been shown to enhance autoimmune disease. In this study, we attempt to reconcile this paradox by deletion of CD24 (24KO) in a lupus-like disease model driven by forced expression of HSP gp96 at the cell surface (transgenic mice [tm]). As expected, tm24KO mice showed increased CD11c(+) dendritic cell activation coupled to a significant increase in dendritic cell-specific IL-12 production compared with tm mice. However, tm24KO mice showed less CD4 T cell activation and peripheral inflammatory cytokine production in comparison with tm mice. We characterized an enhanced immune suppressive milieu in tm24KO mice distinguished by increased TGF-β and greater regulatory T cell-suppressive capacity. We found greater absolute numbers of myeloid-derived suppressor cells (MDSCs) in tm24KO mice and showed that the Ly6...

Research paper thumbnail of Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies

Although results from preclinical studies in animal models have proven the con- cept for use of a... more Although results from preclinical studies in animal models have proven the con- cept for use of anti-cytotoxic T-lympho- cyte antigen 4 (CTLA-4) antibodies in cancer immunotherapy, 2 major obstacles have hindered their successful applica- tion for human cancer therapy. First, the lack of in vitro correlates of the antitumor effect of the antibodies makes it difficult to screen for the